263.89MMarket Cap-1196P/E (TTM)
0.961High0.912Low488.30KVolume0.950Open0.921Pre Close455.49KTurnover0.24%Turnover RatioLossP/E (Static)279.22MShares3.25652wk High0.50P/B192.42MFloat Cap0.85052wk Low--Dividend TTM203.60MShs Float19.840Historical High--Div YieldTTM5.26%Amplitude0.850Historical Low0.932Avg Price1Lot Size
Lyell Immunopharma Stock Forum
Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with aggressive relapsed/refractory B-cell non-Hodgkin’s lymphoma
Presenting initial data from Phase 1 multi-center clinical trial of IMPT-314 at the American Society of Hematology 2024...
05/11/2024 - 22:30
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, ...
Dow Jones· just
$Lyell Immunopharma (LYEL.US)$
$Edible Garden (EDBL.US)$ 👍
No comment yet